[Adverse effects of parenteral administration of antisense oligonucleotides].
To characterize the toxicity of phosphorothioate antisense oligodeoxynucleotides ([S]ODNs) in vivo, the mice received intravenously 26-mer bcr-abl antisense oligodeoxynucleotides (1 mg/mice/day) for 9 consecutive days. The organs and tissues were removed on the indicated days (+1, +7, +30) after the treatment. Our investigation revealed middle elevation of aminotransferases activity, lactate dehydrogenase level, total protein level and globulin level, decrease of glucose, albumin and blood urea nitrogen level in the peripheral blood. The mild anaemia and thrombocytopenia were observed too. The most significant treatment-related findings in the antisense treated mice were splenomegaly, reactive hepatitis and atrocytosis of kidney. These findings together with previous results demonstrate little and temporary toxicity effects mainly in organs known from cumulating of [S]ODNs.
Białek
A
A
Klinika Gastroenterologii Instytutu Chorób Wewnetrznych Pomorskiej Akademii Medycznej w Szczecinie.
Kawalec
M
M
Hoser
G
G
Kawiak
J
J
Krygier-Stojałowska
A
A
Skórski
T
T
Marlicz
K
K
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D001806:Blood Urea Nitrogen; D004305:Dose-Response Relationship, Drug; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D013997:Time Factors; D014018:Tissue Distribution; D000637:Transaminases / Q000378:metabolism
D001786:Blood Glucose; D001798:Blood Proteins; D016376:Oligonucleotides, Antisense; D007770:L-Lactate Dehydrogenase; D000637:Transaminases; D016044:Fusion Proteins, bcr-abl